Loading…
← CockpitCompetitor Analysis › 600276.SS Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class AOpen in the cockpit ↗

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A600276.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

China's largest innovative drugmaker, developing oncology, metabolic and autoimmune drugs alongside a generics business.

≈ China's Eli Lilly/Pfizer in miniatureMomentum strong 74
Mkt cap
$45.7B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$435M
20-day average traded
Fwd P/E
33.4×
forward earnings
ROIC−WACC
+22.9 pp
WACC 6.8%
Hurdle
+11 pp
Req g minus delivered
Next earnings
152 days
19 Apr 2027
Close · CNYCN¥46.90
1D-1.6%
1W-2.7%
1M-1.2%
3M-12.8%
6M-13.1%
YTD-21.3%
1Y-24.3%
ATR %2.8%
52w lowhigh28.8% off high

What Jiangsu Hengrui Pharmaceuticals does

China's largest innovative drugmaker, developing oncology, metabolic and autoimmune drugs alongside a generics business.

Sells to Chinese hospitals through a large sales force and also earns upfront and milestone payments when it licenses drugs to foreign companies. Over the past decade it has moved from mainly generics toward its own new drugs, which are now the main driver. It is controlled through a holding company associated with chairman Sun Piaoyang and added a Hong Kong listing in 2025.

In one line: China's Eli Lilly/Pfizer in miniature.

Products and services

  • Oncology drugs
  • Metabolic/diabetes drugs (incl. GLP-1)
  • Generic/anesthesia drugs
  • Autoimmune/other innovative pipeline

Customers

  • Hospitals
  • Pharmacy distributors
  • Licensing partners (global pharma)

Where it sits in the supply chain

  • Health care
  • Pharmaceuticals
  • Innovative drug R&D, generics…

What could go right

  • Out-licensing deals to global pharma
  • China oncology/metabolic drug market growth

What could go wrong

  • China drug-pricing (volume-based procurement) pressure
  • Patent-cliff on legacy generics

Moat: narrow (IP / patents, scale, brand). Largest domestic R&D pipeline and sales force among Chinese pharma, with growing licensing deals to global players.

Headquarters: Lianyungang, China · Founded: 1970 · Employees: 20,602

Named competitors

Jiangsu Hengrui Pharmaceuticals at a glance

Size Jiangsu Hengrui Pharmaceuticals (600276.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $45.7B, the 35th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥46.90 on 18 Nov 2026.

Performance Over six months the shares fell 13.1%, against +16.9% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 6.0% over the last twelve months (peer median +14.0%); the operating margin is 27.4% (peer median 19.0%).

Valuation It trades at 33.4× forward earnings against a peer median of 19.0× (6th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 22.9 points above its cost of capital (6.8% WACC).

Next results Next results expected around 19 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 115600276.SS 89
Six months, rebased to 100: Jiangsu Hengrui Pharmaceuticals against the median of its 20 peers (local-currency closes).

Jiangsu Hengrui Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥32.9BCN¥31.4BCN¥27.8BCN¥22.6BCN¥21.1B
Revenue growth—+13%+23%+7%—
Gross profitCN¥28.9BCN¥26.7BCN¥23.6BCN¥18.7BCN¥17.4B
EBITDAn/aCN¥8.96BCN¥7.27BCN¥4.90BCN¥3.66B
Net incomeCN¥8.88BCN¥7.71BCN¥6.34BCN¥4.30BCN¥3.91B
Free cash flowCN¥6.11BCN¥8.32BCN¥5.51BCN¥6.26B-CN¥560M
Capital expenditureCN¥3.92BCN¥2.96BCN¥1.97BCN¥1.48BCN¥1.99B
Total debtCN¥422MCN¥938MCN¥669MCN¥629MCN¥1.70B

Quarterly statements and history in the cockpit →

Jiangsu Hengrui Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%+20%688235SUNPHARMASDZGALD4578HLNRPRXBIIBZTSBAYN235945034568DIVISLAB4502MRKROIV4519INSM3692600276.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Hengrui Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%+40%20×40×60×688235SUNPHARMASDZGALD4578HLNRPRXBIIBZTS235945034568DIVISLAB450245193692600276.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Hengrui Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%688235SUNPHARMASDZGALD4578HLNRPRXZTS23594503DIVISLAB3692600276.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jiangsu Hengrui Pharmaceuticals is the large dot.

Jiangsu Hengrui Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (600276.SS vs 688235.SS vs 1801.HK vs LLY)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
BeOne Medicines 688235.SS$45.5B+9%+25%18%59.7×19.1%
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%

How Jiangsu Hengrui Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Hengrui Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure600276.SSPeer medianRank in peer set
1-month return-1.2%+7.0%4th lowest of 21
6-month return-13.1%+16.9%lowest of 21
Distance from 52-week high-28.8%-7.6%4th lowest of 21
Revenue growth (TTM)+6.0%+14.0%7th lowest of 21
Operating margin27.4%19.0%7th highest of 21
Forward P/E33.4×19.0×6th most expensive of 19
Growth the price implies (Req g, 7 yrs)13.4%7.6%5th most demanding of 18
Growth delivered (Del g)+2.7%+8.9%5th lowest of 18
Hurdle (Req g minus delivered)+10.7 pp-2.9 pp5th most demanding of 18
ROIC minus cost of capital+22.9 pp+4.4 pp5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Wuxi Apptec 2359.HKHong Kong$64.1B+51%+38%44%19.5×8.4%+20.4%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%

Questions

Who are Jiangsu Hengrui Pharmaceuticals's main competitors?
Named competitors: BeiGene (688235.SS), Innovent Biologics (1801.HK), Eli Lilly (LLY), Pfizer (PFE). The cockpit's measured peer set (industry) also includes BeOne Medicines (688235.SS), Sun Pharmaceutical Industries (SUNPHARMA.NS), Sandoz (SDZ.SW), Galderma (GALD.SW), Otsuka Hldgs (4578.T), Haleon (HLN.L).
Is Jiangsu Hengrui Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 33.4× against a peer median of 19.0×, 6th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jiangsu Hengrui Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -13.1% against +16.9% for the median peer; over one year -24.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.